TREATMENT OF CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION IN PATIENTS WITH HYPERTENSION DISEASE: POTENTIAL THERAPEUTIC ROLE OF STATINES

Abstract

The prospective randomized trial included 167 patients with functional class II-III of chronic heart failure (CHF) and a preserved left ventricular ejection fraction (LVEF) affected by hypertensive disease of stage III. In addition to antihypertensive therapy with perindopril and verapamil SR (n = 85) or amlodipine (n = 82), atorvastatin was prescribed, which was regularly taken by 50.6% and 48.8% of patients, respectively. After 12 months, patients in each treatment arm showed improvement in the clinical condition and quality of life, an increase in 6MWD (6-minute walk distance). The patients receiving atorvastatin demonstrated a significant reduction in the N-terminal prohormone of brain natriuretic peptide (NT-proBNP or BNPT) level, and a tendency to improve a diastolic LV function. Adding atorvastatin to the therapy of CHF with preserved LVEF may reasonably improve the prognosis of patients.

Keywords

• heart failure
• preserved ejection fraction
• atorvastatin
• verapamil
• amlodipine
• left ventricle
• diastolic function